Anti-TNF Drug
PreclinicalSmall molecule
Anti-TNF Drug is one of 51 small molecule programs targeting Complication. It is currently in Preclinical.
2
Indications
3
Total Trials
1
Active Trials
50
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
67 competitors in Crohn's Disease
#DrugCompanyPhaseTrials
1Remicade
Johnson & JohnsonApproved
Entyvio
TakedaApproved
Humira
RRanbaxy Laboratories Limited
Approved
Omvoh
Eli LillyApproved
Imuran
LLegacy Health System
Approved
Trexall
Jazz PharmaceuticalsApproved
Epidiolex
Jazz PharmaceuticalsApproved
Levulan
Sun Pharmaceutical Industries, Inc.Approved
Opzelura
PfizerApproved
Mycobutin
PfizerApproved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Anti-TNF Drug. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- HHospices Civils de Lyon